Head to Head Survey: Quoin Pharmaceuticals (NASDAQ:QNRX) and Apyx Medical (NASDAQ:APYX)

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) and Apyx Medical (NASDAQ:APYX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Quoin Pharmaceuticals and Apyx Medical’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$9.38 million	($4.93)	-0.09
Apyx Medical	$44.16 million	4.71	-$23.18 million	($0.60)	-10.02

Quoin Pharmaceuticals has higher earnings, but lower revenue than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.1% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 65.6% of Apyx Medical shares are owned by institutional investors. 36.6% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 11.6% of Apyx Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Quoin Pharmaceuticals and Apyx Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	0	1	1	0	2.50
Apyx Medical	0	1	2	0	2.67

Quoin Pharmaceuticals presently has a consensus target price of $15.00, suggesting a potential upside of 3,309.09%. Apyx Medical has a consensus target price of $6.33, suggesting a potential upside of 5.38%. Given Quoin Pharmaceuticals’ higher probable upside, analysts plainly believe Quoin Pharmaceuticals is more favorable than Apyx Medical.

Profitability

This table compares Quoin Pharmaceuticals and Apyx Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-169.43%	-76.78%
Apyx Medical	-46.93%	-51.04%	-37.12%

Volatility and Risk

Quoin Pharmaceuticals has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Apyx Medical has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

Summary

Apyx Medical beats Quoin Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About Quoin Pharmaceuticals

(Get Rating)

Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.

About Apyx Medical

(Get Rating)

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.